title: Risk of tuberculosis with the use of anti-TNF medications in psoriasis: incidence, screening and management.
abstract: Tumor necrosis factor (TNF) plays an important role in containing mycobacterial infections. With the rapidly increasing role of TNF inhibitors in dermatology, tuberculosis (TB) is becoming an important and worrisome concern to dermatologists. This paper aims to provide a comprehensive review on the incidence of TB in patients treated with anti-TNF, the variety of TB screening methods, and management of these cases. Various national recommendations have been highlighted. The monoclonal antibodies, infliximab and adalimumab, appear to be more associated with the risk of TB reactivation than the soluble receptor etanercept. Tuberculosis associated with TNF inhibitors, in contrast to classical TB, is more likely to be disseminated, atypical, extra pulmonary, and life threatening. Vigilance for typical and atypical presentations of active TB is mandatory until the end of therapy. Although tuberculin standard test (TST) has been the gold standard for screening of latent TB infection (LTBI) for close to a century, it has several inadequacies and may be unreliable in patients with widespread psoriasis. Interferon gamma release assays (IGRAs) with better diagnostic specificity and sensitivity are a promising adjunct to diagnose LTBI at present. Although appropriate screening and treatment of LTBI will lower the risk of reactivation to a great extent, no chemoprophylactic regimen is fully protective.
authors.forename: Vijayalakshmi
authors.initials: V
authors.lastname: Kasiraman
authors.affiliation: Cardiff University.
authors.forename: Ausama A
authors.initials: AA
authors.lastname: Atwan
authors.forename: Oyewole Chris
authors.initials: OC
authors.lastname: Durojaiye
authors.forename: Manju
authors.initials: M
authors.lastname: Kalavala
authors.forename: Vincent
authors.initials: V
authors.lastname: Piguet
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D014943:Global Health; D006801:Humans; D015994:Incidence; D000069285:Infliximab; D008403:Mass Screening; D011565:Psoriasis / Q000188:drug therapy*; D014376:Tuberculosis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab